HomeCompareINVVY vs ORCC

INVVY vs ORCC: Dividend Comparison 2026

INVVY yields 2.91% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 INVVY wins by $2.7K in total portfolio value· pulled ahead in Year 4
10 years
INVVY
INVVY
● Live price
2.91%
Share price
$21.85
Annual div
$0.64
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.1K
Annual income
$350.58
Full INVVY calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — INVVY vs ORCC

📍 INVVY pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodINVVYORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, INVVY + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
INVVY pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

INVVY
Annual income on $10K today (after 15% tax)
$247.08/yr
After 10yr DRIP, annual income (after tax)
$297.99/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, INVVY beats the other by $297.11/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of INVVY + ORCC for your $10,000?

INVVY: 50%ORCC: 50%
100% ORCC50/50100% INVVY
Portfolio after 10yr
$22.7K
Annual income
$175.81/yr
Blended yield
0.77%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

INVVY
Analyst Ratings
1
Hold
Consensus: Hold
Price Target
$50.00
+128.9% upside vs current
Range: $50.00 — $50.00
Altman Z
2.8
Piotroski
2/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

INVVY buys
0
ORCC buys
0
No recent congressional trades found for INVVY or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricINVVYORCC
Forward yield2.91%9.79%
Annual dividend / share$0.64$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$24.1K$21.4K
Annual income after 10y$350.58$1.04
Total dividends collected$3.2K$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusHoldBuy
Analyst price target$50.00$16.00

Year-by-year: INVVY vs ORCC ($10,000, DRIP)

YearINVVY PortfolioINVVY Income/yrORCC PortfolioORCC Income/yrGap
1$10,991$290.68$11,190$489.61$199.00ORCC
2$12,059$298.57$12,229$256.01$170.00ORCC
3$13,209$306.15$13,216$130.74$7.00ORCC
4← crossover$14,447$313.42$14,207$66.02+$240.00INVVY
5$15,779$320.37$15,234$33.17+$545.00INVVY
6$17,210$327.01$16,317$16.62+$893.00INVVY
7$18,748$333.34$17,468$8.32+$1.3KINVVY
8$20,400$339.38$18,695$4.16+$1.7KINVVY
9$22,173$345.12$20,006$2.08+$2.2KINVVY
10$24,076$350.58$21,407$1.04+$2.7KINVVY

INVVY vs ORCC: Complete Analysis 2026

INVVYStock

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Full INVVY Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this INVVY vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

INVVY vs SCHDINVVY vs JEPIINVVY vs OINVVY vs KOINVVY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.